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cyclin H-CDK7は，CDK-activating kinase （CAK）



































試薬： Flavopiridol hydrochloride, 2-（ 2-
Chlorophenyl）-5,7-dihydroxy-8-[（3r,4s）-3-
hydroxy-1-methyl-4-piperidinyl]-4h-1-benzopyran-4-
one hydrochloride （Sigma, St. Louis, MO），
R P M I 1 6 4 0培地，牛胎児血清（F B S）， 1 0 %
trypsin-EDTA，MTT assay kit （以上Sigma），
TranSignal Human Cytokine Antibody Array 3.0 kit
（Panomics, Redwood City, CA），ヒト遺伝子組み
換え IL-6（分子量約24kD）， IL-8，RANTES
（ Regulated upon Activation, Normal T-cell




polymerase II （pol II）（N-20），phospho-Ser5 Pol
II （clone 8A7） （以上Santa Cruz Biotechnology




















量の2x SDS-PAGE sample buffer （100mM Tris-
HCl pH 6.8, 4% SDS, 20% Glycerol, 20% β-mercap-
toethanol and 0.02% Bromophenol blue）を準備し，
SDS-PAGEゲル（7%, 10% or 15%）に添加し泳動
した．ゲル内に分画された蛋白は Immobilon-P
0.45 μm PVDF membrane （Millipore, Billerica,
MA）に転写し，抗体とTBS-T （25 mM Tris,
130mM NaCl, pH 8.4，5 mM リン酸2水素カリウ
ム, 5%ドライミルク，0.1% Tween 20）を用いて
培養した．
サイトカイン抗体アレイ解析：サイトカイン
抗体アレイ（TranSignal Human Cytokine Antibody





Chemiluminescence Image Analyzer （ Alpha
Innotech, San Leandro, CA）にて可視化した．
統計処理：図４，図５におけるデータ群間の
検定は，ANOVA分散分析と多重比較のpost hoc














VEGF，soluble TNFα receptor I，eotoxin，cyto-
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し，細胞蛋白の転写活性を抑制する事が近年明
らかにされている22）． FlavopiridolのThyL-6細胞













とし，RNA polymerase II （pol II） のCOOH-ter-
minal domain（CTD）リン酸化を阻害する可能性
が想定されている 17）．ThyL-6細胞に見られた
FlavopiridolのRNA pol II 転写阻害活性を検討する
ために100nM Flavopiridol存在下に4時間培養し，
ThyL-6細胞のIL-6もしくはRNA polymerase II




RNA pol II の２つのサブユニット（IIoとIIa）の
うち，RNA pol IIのDNAへの結合期（initiation）
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ど抗アポトーシス蛋白転写抑制の可能性も考え
られる8）．
Flavopiridolはpan CDK inhibitorであり16, 23），
cyclin T-CDK9/cyclin H-CDK7を阻害し，RNA































培養した後，細胞を採取し細胞RNA polymerase II （RNA
pol II）の発現をwestern blotで観察した．上のバンド（IIo）
はリン酸化 RNA pol IIを，下のバンド（IIa）は非リン酸化
RNA pol IIを示す．4時間の薬剤投与によりRNA pol II の
degradationが見られた．
B） RNA pol II degradationはFlavopiridol濃度依存性が観察さ
れた．
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Flavopiridol inhibits interleukin-6 secretion via degradation of RNA
polymerase Ⅱ in multi-cytokine-producing ThyL-6 cells 
originally established from patient with thymus cancer
Kazutaka Takagi 1) Kunihiro Inai2)
Nobuhiro Naiki 2) Hiromichi Iwasaki1) 
Takanori Ueda 1)
1) Hematology and Oncology Division, Faculty of Medical Science, University of Fukui.
2) Division of Molecular Pathology, Faculty of Medical Science, University of Fukui.
Interleukin-6 （IL-6）, an inflammatory cytokine
produced by various cells, regulates production of
acute-phase proteins in liver, and induces proliferation
in IL-6-dependent cells. After IL-6 binds to an IL-6
receptor （IL-6R） on the target cell, the signal acti-
vates gp-130-associated Janus tyrosine kinase （Jak），
which then stimulates transcription, cell proliferation
and cytokine production via signal transducers and
activators of transcription 3 （STAT3）. Monoclonal
anti-IL-6R antibody therapy （tocilizumab , human-
ized monoclonal antibody） has recently been found
to be effective for rheumatoid arthritis （RA）and
some IL-6-dependent cancers, and about 30% of RA
patients have achieved remission by combination use
with methotrexate. Flavopiridol, a semi-synthetic
flavonoid isolated from Dysoxylum binectariferum, is
known to be an inhibitor of pan-cyclin-dependent
kinases （CDKs）. In this paper, we demonstrate that
Flavopiridol inhibits IL-6 production at concentrations
below 100 nM in inflammatory cytokine-producing
cells （ThyL-6）originally established from a 57-
year-old patient with thymus cancer. Moreover,
Flavopiridol was able to inhibit RNA polymerase II
phosphorylation, which is necessary for CDK-7 or
CDK-9 activation, thus suggesting that this flavonoid
drug can inhibit transcription activity at clinically
achievable incubation times and concentrations.In
conclusion, Flavopiridol is a novel therapeutic tool for
IL-6-dependent cancer, and is an anti-inflammation
agent for conventional therapy-resistant rheumatologi-
cal  diseases.
